Live SpaceX Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Minerva Neurosciences, Inc.

Get SEC filing alerts via email and in your feed for Minerva Neurosciences, Inc.

NERV

Minerva Neurosciences, Inc.

About Minerva Neurosciences, Inc.

Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing proprietary therapies for central nervous system disorders. Its key products include roluperidone for negative symptoms in schizophrenia, and in-licensed compounds like MIN-301 for Parkinson’s disease and seltorexant for insomnia and depression. The company targets high unmet medical needs globally, leveraging innovative mechanisms, clinical data, and strategic collaborations to advance novel CNS treatments.
This description was generated via AI from an annual report. Updated 9 months ago.

Latest SEC Filings from Minerva Neurosciences, Inc.

1
1
Minerva Neurosciences, Inc. Minerva Neurosciences Reports $125.4 Million Net Loss in Latest Quarter

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
Minerva Neurosciences, Inc. Minerva Neurosciences Reports $293.4 Million Net Loss for 2025, Plans Phase 3 Trial for Roluperidone

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Minerva Neurosciences, Inc. Minerva Neurosciences Reports $2.7 Million Net Loss in Q3 2025, Prepares for Phase 3 Trial

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Minerva Neurosciences, Inc. Minerva Neurosciences Reports $3.3 Million Net Loss in Q2 2025, Down from $8.2 Million

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Minerva Neurosciences, Inc. Minerva Neurosciences Reports $3.8 Million Net Loss in Q1 2025, Focuses on Roluperidone Development

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Minerva Neurosciences, Inc. Minerva Neurosciences Reports $1.4 Million Net Income for Fiscal Year 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Minerva Neurosciences, Inc. Minerva Neurosciences Reports Net Income Turnaround, Sells Royalty Interest in Seltorexant

Via official filing (AI summary) | over 1 year ago | 0 comments